ML-9

ML-9 was originally identified as a selective Ca²⁺-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca²⁺ concentrations.¹ ML-9 also inhibits PKB/Akt activity with an IC₅₀ range of 10-50 µM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin.² Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC₅₀ = ~20 µM), p90 S6 (IC₅₀ = ~50 µM), and MAP kinase (IC₅₀ = ~35 µM).²

WARNING This product is not for human or veterinary use.

1. Ito, S., Kume, H., Honjo, H., et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca²⁺ concentration in guinea pig trachealis. Eur. J. Pharmacol. 486, 325-333 (2004).

2. Smith, U., Carvalho, E., Mosialou, E., et al. PKB inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not the antilipolytic effect in rat adipocytes. Biochem. Biophys. Res. Commun. 268, 315-320 (2000).